<DOC>
	<DOCNO>NCT02401945</DOCNO>
	<brief_summary>The purpose study evaluate safety efficacy intravitreal ( IVT ) administration DE-120 subject treatment-naive active subfoveal choroidal neovascularization ( CNV ) secondary age-related macular degeneration ( AMD ) .</brief_summary>
	<brief_title>A Safety Efficacy Study DE-120 Injectable Solution Age-related Macular Degeneration</brief_title>
	<detailed_description />
	<mesh_term>Macular Degeneration</mesh_term>
	<criteria>Provide sign write informed consent Diagnosis active CNV secondary wet AMD , subfoveal component study eye No evidence subfoveal fibrosis subfoveal RPE atrophy study eye At least one lesion study eye meet minimal pathology criterion Best correct visual acuity 70 25 ETDRS letter study eye Best correct visual acuity 20/320 good fellow eye Reasonably clear medium fixation study eye Ocular Aphakic anterior chamber intraocular lens study eye Received prior treatment antiVEGF , intravitreal corticosteroid photodynamic therapy study eye Uncontrolled glaucoma despite antiglaucoma therapy study eye Evidence ocular disease AMD study eye may confound outcome study History vitrectomy study eye Need ocular surgery study eye course trial Presence history certain ocular periocular pathology condition could limit ability perform require study assessment either eye and/or confound study result NonOcular Allergy hypersensitivity study drug product , fluorescein dye studyrelated procedure medication Current history certain systemic condition , abnormality therapy would render subject poor candidate study Participation investigational drug device clinical trial within 30 day prior randomization plan participate investigational drug device clinical trial duration study Females pregnant lactating female childbearing potential use adequate contraceptive precaution men agree practice acceptable method contraception throughout course study Unable comply study procedure followup visit</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Macular Degeneration</keyword>
</DOC>